Mr. Conroy has served as our Chief Executive Officer since 2009, and as Chairman of our Board of Directors since 2014. He has been responsible for transforming the organization into one of the world s premier cancer diagnostics companies and contributes his extensive business knowledge, legal and executive leadership experience and strategic counsel to the Board. With more than 20 years in the healthcare and health technology space, Mr. Conroy has a deep understanding of our industry. KEY SKILLS AND EXPERTISE Executive Leadership; Finance, Corporate Strategy, and M&A: Obtained from his tenure as Chief Executive Officer of two major public diagnostics companies, Exact Sciences (Nasdaq: EXAS) and Third Wave Technologies (Nasdaq: TWTI). As our Chief Executive Officer, he has created shareholder value through innovative new technologies and key acquisitions, positioning the Company as a global leader in cancer screening and diagnostics. Diagnostics/Medical Device and Technology; Science, Research, and Development: Acquired significant experience overseeing the development, regulatory approval, and commercialization of diagnostic tests and building a high performing team culture within our Company. While Chief Executive Officer of Exact Sciences, he spearheaded collaborative research efforts to identify highly discriminant cancer biomarkers, leading to the development of Cologuard and Cologuard Plus, our proprietary multi-marker tests for the early detection of colorectal cancer. Pipeline Development/Commercialization; Global Business Perspective: In his current role as Chief Executive Officer, he has led the Company through the regulatory approval and commercialization of Cologuard - the first cancer diagnostic test to receive simultaneous FDA approval and national Medicare coverage. Additionally, he led the Company through development of innovative new tests such as Cologuard Plus TM , Oncodetect TM , and Cancerguard TM . Separately, while serving as Chief Executive Officer of Third Wave Technologies, he was responsible for the successful development oversight of Cervista, a cervical cancer screening test. His insight and global perspective into the development, regulatory approval and commercialization processes of diagnostic tests provides valuable insight to the Board in shaping our business strategy. CAREER HIGHLIGHTS Exact Sciences (Nasdaq: EXAS) President, Chairman and Chief Executive Officer (since 2009, Chairman since 2014) Third Wave Technologies , (Nasdaq: TWTI) (acquired by Hologic, Inc. in 2008) molecular diagnostics business President and Chief Executive Officer (2005-2008) General Counsel (2004-2005) GE Healthcare healthcare technology arm of General Electric (NYSE: GE) Intellectual Property Counsel (2002-2004) EDUCATION B.S., Electrical Engineering, Michigan State University J.D., University of Michigan